These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 26497927)

  • 1. Chronic effects of losartan on the muscles and the serologic profiles of mdx mice.
    Lee EM; Kim DY; Kim AY; Lee EJ; Kim SH; Lee MM; Sung SE; Park JK; Jeong KS
    Life Sci; 2015 Dec; 143():35-42. PubMed ID: 26497927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.
    Spurney CF; Sali A; Guerron AD; Iantorno M; Yu Q; Gordish-Dressman H; Rayavarapu S; van der Meulen J; Hoffman EP; Nagaraju K
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):87-95. PubMed ID: 21304057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice.
    Lee EJ; Kim AY; Lee EM; Lee MM; Min CW; Kang KK; Park JK; Hwang M; Kwon SH; Tremblay JP; Jeong KS
    Pathol Int; 2014 Aug; 64(8):388-96. PubMed ID: 25143127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute AT
    Meyers TA; Heitzman JA; Krebsbach AM; Aufdembrink LM; Hughes R; Bartolomucci A; Townsend D
    J Mol Cell Cardiol; 2019 Mar; 128():51-61. PubMed ID: 30664850
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin II receptor blockade administered after injury improves muscle regeneration and decreases fibrosis in normal skeletal muscle.
    Bedair HS; Karthikeyan T; Quintero A; Li Y; Huard J
    Am J Sports Med; 2008 Aug; 36(8):1548-54. PubMed ID: 18550776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).
    Morales MG; Cabrera D; Céspedes C; Vio CP; Vazquez Y; Brandan E; Cabello-Verrugio C
    Cell Tissue Res; 2013 Jul; 353(1):173-87. PubMed ID: 23673415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effects of mouse adipose-derived stem cells and losartan in the skeletal muscle of injured mdx mice.
    Lee EM; Kim AY; Lee EJ; Park JK; Lee MM; Hwang M; Kim CY; Kim SY; Jeong KS
    Cell Transplant; 2015; 24(5):939-53. PubMed ID: 24593934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a long-term treatment with metformin in dystrophic mdx mice: A reconsideration of its potential clinical interest in Duchenne muscular dystrophy.
    Mantuano P; Sanarica F; Conte E; Morgese MG; Capogrosso RF; Cozzoli A; Fonzino A; Quaranta A; Rolland JF; De Bellis M; Camerino GM; Trabace L; De Luca A
    Biochem Pharmacol; 2018 Aug; 154():89-103. PubMed ID: 29684379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice.
    Bish LT; Yarchoan M; Sleeper MM; Gazzara JA; Morine KJ; Acosta P; Barton ER; Sweeney HL
    PLoS One; 2011; 6(6):e20856. PubMed ID: 21731628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.
    Gosselin LE; Williams JE; Personius K; Farkas GA
    Muscle Nerve; 2007 Feb; 35(2):208-16. PubMed ID: 17058274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosis and inflammation are greater in muscles of beta-sarcoglycan-null mouse than mdx mouse.
    Gibertini S; Zanotti S; Savadori P; Curcio M; Saredi S; Salerno F; Andreetta F; Bernasconi P; Mantegazza R; Mora M
    Cell Tissue Res; 2014 May; 356(2):427-43. PubMed ID: 24723230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in calsequestrin, TNF-α, TGF-β and MyoD levels during the progression of skeletal muscle dystrophy in mdx mice: a comparative analysis of the quadriceps, diaphragm and intrinsic laryngeal muscles.
    Barros Maranhão J; de Oliveira Moreira D; Maurício AF; de Carvalho SC; Ferretti R; Pereira JA; Santo Neto H; Marques MJ
    Int J Exp Pathol; 2015 Oct; 96(5):285-93. PubMed ID: 26515458
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing CTGF/CCN2 slows down mdx muscle dystrophy and improves cell therapy.
    Morales MG; Gutierrez J; Cabello-Verrugio C; Cabrera D; Lipson KE; Goldschmeding R; Brandan E
    Hum Mol Genet; 2013 Dec; 22(24):4938-51. PubMed ID: 23904456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restoration of muscle strength in dystrophic muscle by angiotensin-1-7 through inhibition of TGF-β signalling.
    Acuña MJ; Pessina P; Olguin H; Cabrera D; Vio CP; Bader M; Muñoz-Canoves P; Santos RA; Cabello-Verrugio C; Brandan E
    Hum Mol Genet; 2014 Mar; 23(5):1237-49. PubMed ID: 24163134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice.
    Fogagnolo Mauricio A; Minatel E; Santo Neto H; Marques MJ
    Clin Nutr; 2013 Aug; 32(4):636-42. PubMed ID: 23218947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle.
    Gosselin LE; Williams JE; Deering M; Brazeau D; Koury S; Martinez DA
    Muscle Nerve; 2004 Nov; 30(5):645-53. PubMed ID: 15389721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
    Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
    Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P2RX7 purinoceptor: a therapeutic target for ameliorating the symptoms of duchenne muscular dystrophy.
    Sinadinos A; Young CN; Al-Khalidi R; Teti A; Kalinski P; Mohamad S; Floriot L; Henry T; Tozzi G; Jiang T; Wurtz O; Lefebvre A; Shugay M; Tong J; Vaudry D; Arkle S; doRego JC; Górecki DC
    PLoS Med; 2015 Oct; 12(10):e1001888. PubMed ID: 26461208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker.
    Taniguti AP; Pertille A; Matsumura CY; Santo Neto H; Marques MJ
    Muscle Nerve; 2011 Jan; 43(1):82-7. PubMed ID: 21108244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transforming growth factor type beta 1 increases the expression of angiotensin II receptor type 2 by a SMAD- and p38 MAPK-dependent mechanism in skeletal muscle.
    Painemal P; Acuña MJ; Riquelme C; Brandan E; Cabello-Verrugio C
    Biofactors; 2013; 39(4):467-75. PubMed ID: 23460581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.